These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 17211429)

  • 21. Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.
    Ayuk F; Perez-Simon JA; Shimoni A; Sureda A; Zabelina T; Schwerdtfeger R; Martino R; Sayer HG; Alegre A; Lahuerta JJ; Atanackovic D; Wolschke C; Nagler A; Zander AR; San Miguel JF; Kröger N
    Haematologica; 2008 Sep; 93(9):1343-50. PubMed ID: 18641030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcomes following myeloablative allogeneic transplantation for multiple myeloma compared to autologous transplantation and the impact of graft-versus-myeloma effect.
    Khaled Y; Mellacheruvu S; Reddy P; Peres E; Mineishi S
    Bone Marrow Transplant; 2009 Sep; 44(5):325-6. PubMed ID: 19204708
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation.
    Jabbour E; Rondon G; Anderlini P; Giralt SA; Couriel DR; Champlin RE; Khouri IF
    Bone Marrow Transplant; 2007 Sep; 40(5):431-5. PubMed ID: 17603511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
    Bloor AJ; Thomson K; Chowdhry N; Verfuerth S; Ings SJ; Chakraverty R; Linch DC; Goldstone AH; Peggs KS; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):50-8. PubMed ID: 18158961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk assessment in haematopoietic stem cell transplantation: stem cell source.
    Urbano-Ispizua A
    Best Pract Res Clin Haematol; 2007 Jun; 20(2):265-80. PubMed ID: 17448961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimerism and T-cell receptor repertoire analysis after unrelated cord blood transplantation with a reduced-intensity conditioning regimen following autologous stem cell transplantation for multiple myeloma.
    Toubai T; Hirate D; Shono Y; Ota S; Ibata M; Mashiko S; Sugita J; Shigematsu A; Miura Y; Kato N; Umehara S; Kahata K; Tsutsumi Y; Iwao N; Toyoshima N; Tanaka J; Asaka M; Imamura M
    Int J Lab Hematol; 2008 Feb; 30(1):75-81. PubMed ID: 18190473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [IV. Drug discovery for bone marrow transplantation in multiple myeloma].
    Saito K
    Gan To Kagaku Ryoho; 2013 May; 40(5):596-600. PubMed ID: 23957068
    [No Abstract]   [Full Text] [Related]  

  • 29. Eruption of lymphocyte recovery or autologous graft-versus-host disease?
    Nellen RG; van Marion AM; Frank J; Poblete-Gutiérrez P; Steijlen PM
    Int J Dermatol; 2008 Nov; 47 Suppl 1():32-4. PubMed ID: 18986483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of conditioning regimens and stem cell sources on donor-type chimerism early after stem cell transplantation.
    Sugita J; Tanaka J; Hashimoto A; Shiratori S; Yasumoto A; Wakasa K; Kikuchi M; Shigematsu A; Miura Y; Tsutsumi Y; Kondo T; Asaka M; Imamura M
    Ann Hematol; 2008 Dec; 87(12):1003-8. PubMed ID: 18636260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complete remission of multiple myeloma after autoimmune hemolytic anemia: possible association with interferon-alpha.
    Gesundheit B; Zelig O; Shapira MY; Ackerstein A; Avgil M; Or R
    Am J Hematol; 2007 Jun; 82(6):489-92. PubMed ID: 17236186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stem cell transplant for first relapse from the multiple myeloma research foundation.
    Anderson KC; Vesole DH
    Oncology (Williston Park); 2006 Dec; 20(14):1818, 1820-1, 1825-6. PubMed ID: 17263130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Haematopoietic stem cell transplantation: current status.
    Kumar L
    Natl Med J India; 2007; 20(3):128-37. PubMed ID: 17867617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of graft-versus-host disease on skin endothelial and epithelial cell chimerism in stem-cell transplant recipients.
    Willemze AJ; Bakker AC; von dem Borne PA; Bajema IM; Vossen JM
    Transplantation; 2009 Apr; 87(7):1096-101. PubMed ID: 19352133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
    Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are we sure we all do the same things? Results from a GITMO survey on basic practices in allogeneic bone marrow transplantation.
    Bonifazi F; Bandini G; Arcese W
    Haematologica; 2002 May; 87(5):449-52. PubMed ID: 12010654
    [No Abstract]   [Full Text] [Related]  

  • 37. Newly diagnosed multiple myeloma: allograft or autograft?
    Gupta D; Kumar L
    Natl Med J India; 2007; 20(6):300-1. PubMed ID: 18335797
    [No Abstract]   [Full Text] [Related]  

  • 38. Depigmented macules following autologous bone-marrow transplant.
    Worswick S; Pirouz A; Lee DJ
    Arch Dermatol; 2011 Dec; 147(12):1460-1. PubMed ID: 22184779
    [No Abstract]   [Full Text] [Related]  

  • 39. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults.
    Gonzalo-Daganzo R; Regidor C; Martín-Donaire T; Rico MA; Bautista G; Krsnik I; Forés R; Ojeda E; Sanjuán I; García-Marco JA; Navarro B; Gil S; Sánchez R; Panadero N; Gutiérrez Y; García-Berciano M; Pérez N; Millán I; Cabrera R; Fernández MN
    Cytotherapy; 2009; 11(3):278-88. PubMed ID: 19308773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of allogeneic stem cell transplantation in multiple myeloma.
    Bruno B; Giaccone L; Sorasio R; Boccadoro M
    Semin Hematol; 2009 Apr; 46(2):158-65. PubMed ID: 19389499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.